Last Updated on January 6, 2024 by The Health Master
Download notification No. S.O. 2465(E) dated 30-05-2022, link given below: The National Pharmaceutical Pricing Authority (NPPA) has further extended the capping on the trade margin of oxygen concentrators for one more month, till the end of June, 2022 vide its notification No. S.O. 2465(E) dated 30-05-2022.
The trade margin rationalisation (TMR) was announced in June, 2021, in the backdrop of increased use of oxygen concentrators during the C-19 pandemic, since the virus mainly affects the respiratory system of a patient, especially those with co-morbidity such as diabetes, cardiac problems, among others.
In an order on May 30, regarding capping the trade margin of oxygen concentrators at first point of sale or price to distributor, for fixation of maximum retail price of the product.
“In continuation to the notifications, capping the trade margin of oxygen concentrator at first point of sale (price to distributor) upto May 31, 2022 is further extended upto June 30, 3022 or till further order,” said the NPPA order.
The Authority in June, 2021, notified that the Government has put a cap on the trade margin of oxygen concentrators at the first point of sale of the product, at 70 per cent.
It has later extended it in November, for six more months, till May 30, 2022 as the order in June was valid only till November 30, 2021.
The period to report stock details of four medical devices – Bare metal stents, drug eluting stent, orthopaedic knee implants and oxygen concentrators was also relaxed from monthly to quarterly basis during the same period.
The Authority, in its meeting held on November 15, noted that the notification issued in June, 2021, related to price regulation of Oxygen Concentrators based on TMR approach is applicable to November 30, 2021.
Recommendations of the Standing Committee on Affordable Medicines and Health Products (SCAMHP) in its fourth and fifth meeting held on May 25 and 30, this year, was also taken into note by the authority, before deciding on the extension of the price regulation period.
“The Authority deliberated upon the matter in detail and was of the opinion that as C-19 pandemic is still a risk to public health; availability of oxygen concentrators at affordable prices must be ensured,” said the minutes to the meeting.
Hence, it was decided that the notification be extended, before it expires, for another six months up to May 30, 2022.
The move resulted in price reduction of 70 out of 252 products and the MRP was reduced up to 54% (up to Rs 54,337). The pricing of oxygen concentrators did not adversely impact domestic production and no disruption in supplies was observed, said NPPA officials.
Latest on National Pharmaceutical Pricing Authority (NPPA)
Latest notifications – DPCO / NPPA
Latest Notifications: EC Act (Essential Commodities Act)
FAQs – On DPCO: Drugs (Prices Control) Order, 2013
Pharmaceuticals and Medical Devices Bureau of India crosses sales of Rs. 100 crores in May 2022
DCGI gives nod to conduct phase III trial of 0.05% Atropine
Doctors now use prefix Med Dr. instead of Dr. :NMC Guidelines
USFDA gives nod to Zydus for Chemotherapy drug
FDA seals illegal manufacturing firm, seizes cosmetics worth ₹7 lakh
Guidelines meant to stop cross Pathy by Doctors
New Clinical Trial: 1st human patient injected with Cancer-killing virus
USFDA declines to approve this Anti-seizure drug
AIOCD seeks 10% trade margin for wholesalers & 20% for retailers
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
